The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- ASCO Immunotherapy Roundup - 3: AZ Set to Harness Rich Pipeline to Pursue Combo Strategy
July 16, 2015
- Quintiles to Make Full-Fledge Entry into Regenerative Medicine, by Opening New Office in Kobe
July 16, 2015
- Sumitomo Dainippon Ties Up with Servier for Commercialization of Latuda in Australia
July 16, 2015
- Takeda Files NDA for Novel Proteasome Inhibitor Ixazomib in US
July 16, 2015
- As 80% Era Looms, 3 Generic Majors Will Emerge as Dominant Suppliers: Sawai
July 16, 2015
- Kowa Grants Chugai Exclusive Marketing Rights in Japan for Peretinoin for Prevention of Recurrence of HCC
July 15, 2015
- ASCO Immunotherapy Roundup - 2: Chugai Has High Hopes for Atezolizumab Combos with Group Portfolios
July 14, 2015
- Takeda Announces Its Plan to Improve Business Practices; Will Add an Outside Expert to Review Board
July 14, 2015
- US FDA Approves Novel Antipsychotic Agent Rexulti: Otsuka, Lundbeck
July 14, 2015
- Merck Serono Names Former Allergan Japan President Leo Lee as New President
July 14, 2015
- BIKEN to Map Out 5-Year Biz Plan, Eyes Collaboration for PIII: Director
July 13, 2015
- BIKEN to Produce and Ship Same Amount of Seasonal Flu Vaccines as Last Season: Director Yamanishi
July 13, 2015
- Takeda Submits Plans to Improve Business Practices
July 13, 2015
- Generic Share Increases to 52.0% in FY2014: JGA
July 13, 2015
- MTPC Files for Partial Change to Remicade Dosage for Psoriasis
July 13, 2015
- Hisamitsu Starts PII/III Study of Analgesic Transdermal Patch in Japan
July 13, 2015
- “Equal Sense of Gratitude and Responsibility” in Wake of New Generic Share Target of 80%: Nippon Chemiphar President
July 10, 2015
- Lilly Japan, Sumitomo Dainippon to Collaborate in Sales of Once-Weekly GLP-1 Receptor Agonist
July 10, 2015
- AZ Divests Rights to Develop, Sell GI Treatment Entocort Worldwide Excluding US to Tillotts
July 10, 2015
- Anti-PCSK9 Antibody Demonstrates Favorable Results in PIII Study for Japanese Patients: Sanofi, Regeneron
July 10, 2015
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…